Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT

被引：195

作者：

Ljungman, P. ^{[1
]}

de la Camara, R. ^{[1
]}

Cordonnier, C. ^{[1
]}

Einsele, H. ^{[1
]}

Engelhard, D. ^{[1
]}

Reusser, P. ^{[1
]}

Styczynski, J. ^{[1
]}

Ward, K. ^{[1
]}

机构：

[1] Karolinska Univ, Huddinge Hosp, Dept Hematol, S-14186 Huddinge, Sweden

来源：

BONE MARROW TRANSPLANTATION | 2008年 / 42卷 / 04期

关键词：

CMV; HHV-6; HHV-7; HHV-8; SCT; antiviral drugs;

D O I：

10.1038/bmt.2008.162

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twenty-nine of these studies were prospective randomized trials. For the other herpesviruses, HHV-6, -7 and -8, no randomized controlled trial has been performed, although data from some studies with other primary endpoints have been used to assess the management of HHV-6 infection. Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.

引用

页码：227 / 240

页数：14

共 153 条

[1]

[Anonymous], 2000, MMWR Recomm Rep, V49, P1

[2]

[Anonymous], NCCN PRACT GUID ONC

[3] Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection [J].

Avery, RK ;

Bolwell, BJ ;

Yen-Lieberman, B ;

Lurain, N ;

Waldman, WJ ;

Longworth, DL ;

Taege, AJ ;

Mossad, SB ;

Kohn, D ;

Long, JR ;

Curtis, J ;

Kalaycio, M ;

Pohlman, B ;

Williams, JW .

BONE MARROW TRANSPLANTATION, 2004, 34 (12) :1071-1075

[4] Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation [J].

Ayala, E ;

Greene, J ;

Sandin, R ;

Perkins, J ;

Field, T ;

Tate, C ;

Fields, KK ;

Goldstein, S .

BONE MARROW TRANSPLANTATION, 2006, 37 (09) :851-856

[5] Combined Foscarnet-Ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation [J].

Bacigalupo, A ;

Bregante, S ;

Tedone, E ;

Isaza, A ;

VanLint, MT ;

Trespi, G ;

Occhini, D ;

Gualandi, F ;

Lamparelli, T ;

Marmont, AM .

TRANSPLANTATION, 1996, 62 (03) :376-380

[6] Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation [J].

Battiwalla, M. ;

Paplham, P. ;

Almyroudis, N. G. ;

McCarthy, A. ;

Abdelhalim, A. ;

Elefante, A. ;

Smith, P. ;

Becker, J. ;

McCarthy, P. L. ;

Segal, B. H. .

TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (01) :28-32

[7] Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance [J].

Bilgrami, S ;

Aslanzadeh, J ;

Feingold, JM ;

Bona, RD ;

Clive, J ;

Dorsky, D ;

Edwards, RL ;

Tutschka, PJ .

BONE MARROW TRANSPLANTATION, 1999, 24 (01) :69-73

[8]

Blajchman Morris A., 2001, Transfusion Medicine Reviews, V15, P1, DOI 10.1053/tmrv.2001.19946

[9] The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy [J].

Boeckh, M ;

Nichols, WG .

BLOOD, 2004, 103 (06) :2003-2008

[10] Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].

Boeckh, M ;

Leisenring, W ;

Riddell, SR ;

Bowden, RA ;

Huang, ML ;

Myerson, D ;

Stevens-Ayers, T ;

Flowers, MED ;

Cunningham, T ;

Corey, L .

BLOOD, 2003, 101 (02) :407-414

← 1 2 3 4 5 6 7 8 9 10 →